All articles tagged with #23andme
Anne Wojcicki's nonprofit TTAM Research Institute has received court approval to purchase 23andMe's assets for $305 million, ending a bidding war and marking the company's exit from bankruptcy. The deal includes the company's DNA testing services, research operations, and a telehealth subsidiary, with commitments to data privacy and customer protections. The acquisition's future leadership and regulatory challenges remain uncertain.
Anne Wojcicki's nonprofit TTAM Research Institute has been approved to buy back 23andMe for $305 million after the company's bankruptcy, marking a significant turnaround. The deal includes key assets like the DNA testing service and research operations, amid ongoing privacy concerns and legal challenges related to customer data. Wojcicki aims to continue the company's mission to democratize access to genetic information, with commitments to privacy and transparency.
A bankruptcy court approved the $305 million sale of 23andMe to a nonprofit led by former CEO Anne Wojcicki, aiming to prioritize customer privacy and data security, amid ongoing concerns and legal challenges over genetic data handling.
California Attorney General Rob Bonta claims that 23andMe's recent bankruptcy sale of genetic data to TTAM Research Institute does not comply with state privacy laws, specifically the Genetic Information Privacy Act, and is considering further legal action despite court approval of the sale.
A bankruptcy judge approved the sale of 23andMe to a nonprofit led by co-founder Anne Wojcicki, aiming to protect customer DNA data from being sold to third parties amid legal and privacy concerns, with the deal valued at $305 million and ongoing opposition from some states.
23andMe was fined £2.31 million by the UK ICO for a significant data breach in 2023 that exposed sensitive personal information of thousands, including UK residents, due to inadequate security measures. The breach involved credential stuffing attacks, and the company failed to implement proper authentication protocols. Now in bankruptcy, 23andMe is being sold to TTAM Research Institute, which commits to enhancing data protections and consumer rights.
Anne Wojcicki, former CEO of 23andMe, regained control of the genetic testing company by bidding $305 million at auction, outbidding Regeneron Pharmaceuticals, after the company filed for bankruptcy due to declining demand and a data breach. The sale has sparked legal challenges from multiple states over privacy concerns, with a court hearing scheduled to determine the company's future.
Anne Wojcicki, cofounder and former CEO of 23andMe, has agreed to buy back the company's assets for $305 million after a bankruptcy auction, aiming to regain control amid legal and financial challenges, including a significant data privacy controversy and declining revenues.
Anne Wojcicki's nonprofit, TTAM Research Institute, won the bid to acquire 23andMe for $305 million after its bankruptcy, outbidding Regeneron. The deal includes most of 23andMe's assets, and the acquisition aims to continue its mission while addressing privacy concerns. The deal requires court approval scheduled for June 17.
Following 23andMe's financial upheaval and legal challenges, customers can delete their genetic data by logging into their accounts and following specific steps, though some information may still be retained for legal or compliance reasons. It's also advised to revoke consent for research use and check with family members to ensure their data is protected as well.
23andMe, after filing for bankruptcy due to cyberattacks and legal issues, is set to be acquired by TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, in a deal that aims to preserve customer privacy and continue the company's mission, pending court approval amid legal challenges from state attorneys general.
A nonprofit controlled by Anne Wojcicki has won the bid to buy 23andMe out of bankruptcy, potentially allowing Wojcicki to return as CEO. The deal, worth $305 million, raises privacy concerns over genetic data, with legal challenges from states over the sale of genetic information without explicit consent. The sale aims to continue 23andMe's mission of accessible genetic understanding while addressing privacy issues.
Anne Wojcicki is reclaiming control of 23andMe by purchasing its assets through TTAM Research Institute for $305 million after the company's bankruptcy, surpassing an earlier bid from Regeneron Pharmaceuticals, amid ongoing privacy and profitability challenges.
23andMe has agreed to sell its assets, including its genetic testing and research services, to TTAM Research Institute for $305 million, following a court-approved bidding process that included a backup bid from Regeneron. TTAM commits to maintaining privacy policies, enhancing consumer protections, and continuing scientific research, with the transaction subject to court approval scheduled for June 17, 2025.
Following 23andMe's bankruptcy and sale to Regeneron, customers are advised on how to delete or control their genetic data, with steps to request data deletion and revoke research permissions, though some data may still be retained for legal reasons. Customers are also encouraged to inform family members to protect their shared genetic information.